Literature DB >> 11209086

New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches.

O Bruserud 1, B T Gjertsen, B Foss, T S Huang.   

Abstract

In vitro studies of cultured native acute myelogenous leukemia (AML) blasts and cell lines have contributed significantly to our present knowledge about the pathogenesis of AML. In the present article we review different techniques for preparation and in vitro culture of AML blasts. Well-characterized serum-free in vitro conditions can now be used in experimental studies of AML, and this makes comparisons between different studies easier. We also describe assays for characterization of AML progenitor subsets (i.e., suspension cultures, colony assays, long-term in vitro culture, xenotransplantation in immunocompromised mice), and we discuss the possible use of AML cell lines as experimental models in AML. Furthermore, clinical studies suggest that the in vitro growth characteristics of AML blasts assayed by short-term culture of the total native populations can be used as a predictor of prognosis after intensive chemotherapy. These in vitro assays may therefore be used for more accurate identification of prognostic parameters and thereby form a basis for the development of simplified laboratory techniques suitable for routine evaluation of patients undergoing risk-adapted therapy. However, it will be equally important to further evaluate the clinical relevance of assays for primitive AML progenitors, and to develop simplified methods that can be used to characterize these progenitor subsets in the routine clinical evaluation.

Entities:  

Mesh:

Year:  2001        PMID: 11209086     DOI: 10.1634/stemcells.19-1-1

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  30 in total

1.  The constitutive protease release by primary human acute myeloid leukemia cells.

Authors:  Maria Honnemyr; Øystein Bruserud; Annette K Brenner
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-19       Impact factor: 4.553

2.  Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.

Authors:  H Reikvam; A M Øyan; K H Kalland; R Hovland; K J Hatfield; Ø Bruserud
Journal:  Cell Prolif       Date:  2013-10       Impact factor: 6.831

Review 3.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

4.  PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.

Authors:  Maja Grabacka; Wojciech Placha; Krystyna Urbanska; Piotr Laidler; Przemysław M Płonka; Krzysztof Reiss
Journal:  Pigment Cell Melanoma Res       Date:  2008-04-26       Impact factor: 4.693

5.  Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.

Authors:  A Mims; A R Walker; X Huang; J Sun; H Wang; R Santhanam; A M Dorrance; C Walker; P Hoellerbauer; S S Tarighat; K K Chan; R B Klisovic; D Perrotti; M A Caligiuri; J C Byrd; C-S Chen; L James Lee; S Jacob; K Mrózek; C D Bloomfield; W Blum; R Garzon; S Schwind; G Marcucci
Journal:  Leukemia       Date:  2012-11-26       Impact factor: 11.528

6.  Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia.

Authors:  Kah Poh Loh; Janet A Tooze; Barbara J Nicklas; Stephen B Kritchevsky; Jeff D Williamson; Leslie R Ellis; Bayard L Powell; Timothy S Pardee; Neha G Goyal; Heidi D Klepin
Journal:  J Geriatr Oncol       Date:  2019-04-05       Impact factor: 3.599

7.  Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid.

Authors:  Maria Hernandez-Valladares; Rebecca Wangen; Elise Aasebø; Håkon Reikvam; Frode S Berven; Frode Selheim; Øystein Bruserud
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

Review 8.  The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.

Authors:  Håkon Reikvam; Hanne Fredly; Astrid Olsnes Kittang; Oystein Bruserud
Journal:  Toxins (Basel)       Date:  2013-02-18       Impact factor: 4.546

9.  Iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from Streptosporangium sp. induces apoptosis selectively in myeloid leukemia cell lines and patient cells.

Authors:  Lene E Myhren; Gyrid Nygaard; Gro Gausdal; Håvard Sletta; Knut Teigen; Kristin F Degnes; Kolbjørn Zahlsen; Anders Brunsvik; Øystein Bruserud; Stein Ove Døskeland; Frode Selheim; Lars Herfindal
Journal:  Mar Drugs       Date:  2013-01-30       Impact factor: 5.118

10.  Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.

Authors:  G Gausdal; A Wergeland; J Skavland; E Nguyen; F Pendino; N Rouhee; E McCormack; L Herfindal; R Kleppe; U Havemann; F Schwede; O Bruserud; B T Gjertsen; M Lanotte; E Ségal-Bendirdjian; S O Døskeland
Journal:  Cell Death Dis       Date:  2013-02-28       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.